Increased dose single-agent gemcitabine in platinum-taxane resistant metastatic ovarian cancer.

Conclusion: In platinum–taxane resistant epithelial ovarian cancer (EOC), we aimed to determine the effectiveness.

Patients And Methods: Between 2004 and 2013, patients afflicted with platinum–taxane resistant EOC and who were administered a 30-minute i.v.